The Locally Advanced Nonmetastatic Cancer

摘要: At the time of diagnosis, around 20% patients present with a resectable tumor, 50% metastatic disease, and 30% locally advanced unresectable because superior mesenteric artery (SMA) or celiac encasement but nonmetastatic. Despite advances in chemoradiation (CRT) improved systemic chemotherapeutic agents, those who disease suffer both from high rates distant failure local progression, median survival ranging 5 to 11 months. In past 30 years, modest improvements have been attained for tumors treated by CRT chemotherapy (CT) protocols. However, no significant impact on long-term has accomplished. Optimal therapy pancreatic carcinoma remains controversial. A recent systematic review concluded that there is standard treatment cancers, two options: gemcitabine-based CT CRT. These approaches are complementary should be considered. An induction followed nonprogressive promising strategy whose validation ongoing phase III trial.